# EDGAR Filing Document

**Accession Number:** 0001770787
**File Stem:** 0001628280-26-041651
**Filing Date:** 2026-6
**Character Count:** 6414
**Document Hash:** dd4bcd12728745420fce712e8821c8d1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-041651.hdr.sgml**: 20260608

**ACCESSION NUMBER**: 0001628280-26-041651

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260604

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260608

**DATE AS OF CHANGE**: 20260608

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 10x Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001770787
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455614458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39035
- **FILM NUMBER:** 261073346

**BUSINESS ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** (925) 401-7300

**MAIL ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 10X Genomics, Inc.
- **DATE OF NAME CHANGE:** 20190315

?xml version='1.0' encoding='ASCII'? txg-20260604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**______________________**

**FORM 8-K**

**______________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 4, 2026**

![Logo-10x.jpg](txg-20260604_g1.jpg)

**10x Genomics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39035** | **45-5614458** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**6230 Stoneridge Mall Road**

**Pleasanton, California 94588**

**(925) 401-7300**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**___________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol** | **Name of each exchange**<br>**on which registered** |
| **Class A common stock, par value $0.00001 per share** | **TXG** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders**

The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 4, 2026 via live webcast (the "Annual Meeting"). At the Annual Meeting, there were present, virtually or by proxy, holders of 117,542,161 shares of the Company's Class A and Class B common stock, representing 198,815,518, or approximately 90.5%, of the 219,700,782 eligible votes, constituting a quorum. The matters submitted to a vote at the Annual Meeting and the final voting results of such matters were as follows:

***Proposal 1 - Election of Directors*** 

The Company's stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company's 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or until his earlier resignation or removal. The final voting results were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Nominee | Votes For | Votes Against | Abstentions | Broker Non-Votes |
| Serge Saxonov | 164137381 | 15559860 | 557329 | 18560948 |
| Benjamin J. Hindson | 162942766 | 16761532 | 550270 | 18560950 |
| John R. Stuelpnagel | 155628365 | 24072179 | 554023 | 18560951 |

---

***Proposal 2 - Ratification of Independent Registered Public Accounting Firm*** 

The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026. There were no broker non-votes on this proposal. The final voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 197,719,939 | 458,231 | 637,346 |  |

---

***Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers*** 

The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026. The final voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 176,677,540 | 2,828,730 | 748,296 | 18,560,952 |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | 10x Genomics, Inc. | 10x Genomics, Inc. |
| | By: | /s/ Randy Wu |
| | Name: | Randy Wu |
| | Title: | General Counsel and Secretary |
| Date: June 8, 2026 |  |  |

---